Boehringer Ingelheim, a pharmaceutical company, completed the acquisition of Northern Biologics, a provider of therapeutic antibodies. Financial terms were not disclosed. "This acquisition provides Boehringer Ingelheim with two complementary assets to our existing cancer immunology portfolio and supports our strategy to target ‘cold’ tumors with synergistic combination approaches. Driving innovation in tumor stroma and myeloid cell biology is yet another example of how we are ‘Taking Cancer On’ by exploring first-in-class approaches to provide the best treatment options for cancer patients," Jonathon Sedgwick, Boehringer Ingelheim Senior Vice President.